Cassava Sciences, Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational dia…
Biotechnology
US, Austin [HQ]
Investor Relations
Filing Reader · Print Documents · Transcripts
Could not find a transcript
Peer Group
Peers Analysis-
Sorry! None of SAVA's peers has listed transcripts.
Upcoming Transcript Tools
- Full Text Search - Across All Transcripts
- Detail Speaker Profiles
- Non-US Transcripts